155 related articles for article (PubMed ID: 37475123)
1. Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders.
Papola D; Ostuzzi G; Todesco B; Gastaldon C; Hanna F; Chatterjee S; van Ommeren M; Barbui C
Lancet Psychiatry; 2023 Oct; 10(10):809-816. PubMed ID: 37475123
[TBL] [Abstract][Full Text] [Related]
2. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
[TBL] [Abstract][Full Text] [Related]
3. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
4. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward.
Jenei K; Aziz Z; Booth C; Cappello B; Ceppi F; de Vries EGE; Fojo A; Gyawali B; Ilbawi A; Lombe D; Sengar M; Sullivan R; Trapani D; Huttner BD; Moja L
Lancet Glob Health; 2022 Dec; 10(12):e1860-e1866. PubMed ID: 36183737
[TBL] [Abstract][Full Text] [Related]
5. Medicines for cancers in children: The WHO model for selection of essential medicines.
Robertson J; Magrini N; Barr R; Forte G; Ondari C
Pediatr Blood Cancer; 2015 Oct; 62(10):1689-93. PubMed ID: 25929524
[TBL] [Abstract][Full Text] [Related]
6. Mapping the selection, availability, price and affordability of essential medicines for mental health conditions at a global level.
Todesco B; Ostuzzi G; Barbui C
Epidemiol Psychiatr Sci; 2022 Apr; 31():e22. PubMed ID: 35438063
[TBL] [Abstract][Full Text] [Related]
7. Access and use of WHO essential medicines in Italy.
Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
[TBL] [Abstract][Full Text] [Related]
8. Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.
Jeličić Kadić A; Žanić M; Škaričić N; Marušić A
PLoS One; 2014; 9(10):e111474. PubMed ID: 25337860
[TBL] [Abstract][Full Text] [Related]
9. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases.
Kishore SP; Blank E; Heller DJ; Patel A; Peters A; Price M; Vidula M; Fuster V; Onuma O; Huffman MD; Vedanthan R
J Am Coll Cardiol; 2018 Feb; 71(5):564-574. PubMed ID: 29406862
[TBL] [Abstract][Full Text] [Related]
10. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
[TBL] [Abstract][Full Text] [Related]
11. Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?
Osorio-de-Castro CGS; Azeredo TB; Pepe VLE; Lopes LC; Yamauti S; Godman B; Gustafsson LL
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):402-412. PubMed ID: 29117642
[TBL] [Abstract][Full Text] [Related]
12. Essential medicines for emergency care in Africa.
Broccoli MC; Pigoga JL; Nyirenda M; Wallis L; Calvello Hynes EJ
Emerg Med J; 2018 Jul; 35(7):412-419. PubMed ID: 29627770
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of essential medicines lists: the South African case study.
Perumal-Pillay VA; Suleman F
BMC Health Serv Res; 2016 Dec; 16(1):687. PubMed ID: 27955710
[TBL] [Abstract][Full Text] [Related]
14. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
[TBL] [Abstract][Full Text] [Related]
15. Expanding medicines for neurologic disorders on the WHO Model List.
Rimmer K; Shah H; Thakur K
Neurology; 2017 Mar; 88(10):e87-e91. PubMed ID: 28265046
[TBL] [Abstract][Full Text] [Related]
16. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
Mahmić-Kaknjo M; Marušić A
Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
[TBL] [Abstract][Full Text] [Related]
17. The interpretation of China national essential medicines list 2018.
Zuo W; Mei D; Sun W; Tang X; Niu Z; Gao D; Zhang B
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):191-200. PubMed ID: 31914825
[No Abstract] [Full Text] [Related]
18. Mapping actions to improve access to medicines for mental disorders in low and middle income countries.
Barbui C; Dua T; Kolappa K; Saraceno B; Saxena S
Epidemiol Psychiatr Sci; 2017 Oct; 26(5):481-490. PubMed ID: 28067194
[TBL] [Abstract][Full Text] [Related]
19. Essential medicines for mental disorders: comparison of 121 national lists with WHO recommendations.
Todesco B; Ostuzzi G; Gastaldon C; Papola D; Barbui C
Arch Public Health; 2023 Jan; 81(1):8. PubMed ID: 36653880
[TBL] [Abstract][Full Text] [Related]
20. National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis.
Peacocke EF; Myhre SL; Foss HS; Gopinathan U
PLoS Med; 2022 Mar; 19(3):e1003944. PubMed ID: 35275938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
